Education
About Us
Working with TipRanks
Follow Us
AlzChem Group AG (DE:ACT)
XETRA:ACT
Top Page
AlzChem Group AG
(XETRA:ACT)
Select Model
Select Model
Rating:72Outperform
Price Target:
€161.00
▲(15.00% Upside)
AlzChem Group AG's strong financial performance and positive earnings call are the most significant factors contributing to its score. Despite challenges in certain segments and high valuation, the company's robust growth in Specialty Chemicals and strategic investments support a favorable outlook.
AlzChem Group AG (ACT) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.57B
Dividend Yield1.29%
Average Volume (3M)20.69K
Price to Earnings (P/E)27.0
Beta (1Y)0.41
Revenue Growth1.03%
EPS Growth25.48%
CountryDE
Employees1,541
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)1.61
Shares Outstanding10,176,335
10 Day Avg. Volume15,459
30 Day Avg. Volume20,688
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.82
Price to Sales (P/S)1.05
P/FCF Ratio9.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€165.25Price Target Upside18.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AlzChem Group AG Business Overview & Revenue Model
Company DescriptionAlzChem Group AG (ACT) is a leading chemical company based in Germany, specializing in the production of specialty chemicals and high-performance materials. The company operates primarily in the sectors of agriculture, pharmaceuticals, and industrial applications. AlzChem offers a diverse range of products, including fertilizers, chemical intermediates, and advanced materials, focusing on sustainability and innovation to meet the needs of its global customer base.
How the Company Makes MoneyAlzChem Group AG generates revenue through multiple key streams, primarily by selling its specialty chemicals and performance materials to various industries. The company's main revenue sources include the production and sale of ammonium sulfate, which is used in fertilizers, and other chemical intermediates that serve sectors such as agriculture and pharmaceuticals. Additionally, AlzChem benefits from strategic partnerships with companies in its supply chain, which enhance its market reach and operational efficiency. The company's focus on research and development allows it to innovate and create high-value products, further driving revenue growth. Fluctuations in raw material prices and economic conditions can impact its earnings, but the company aims to maintain a competitive edge through quality and sustainability initiatives.
AlzChem Group AG Earnings Call Summary
Earnings Call Date:Oct 30, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Feb 27, 2026
Earnings Call Sentiment Positive
The earnings call highlighted strong growth in the Specialty Chemicals segment and successful strategic partnerships, with overall positive financial performance and significant investments in future growth. However, challenges remain in the Basics & Intermediates segment and due to high electricity costs.Q3-2025 Updates
Positive Updates
Specialty Chemicals Segment Growth
The Specialty Chemicals segment recorded a 9% increase in sales, driving overall growth. EBITDA for this segment increased by 16%, with a margin improvement to almost 28%.
EBITDA and Margin Improvement
EBITDA grew by 12% to EUR 86 million, with the margin increasing from 18.5% to 20.3%, attributed to positive developments in Specialty Chemicals.
Creatine Expansion and Cooperation with Ehrmann
An expansion of creatine production was successfully commissioned, and a notable cooperation with Ehrmann for high-protein creatine products was launched.
CapEx Activities and New Plant Developments
Construction of new plants is on schedule and budget, with significant CapEx investments supporting future growth.
Positive Group Net Result
The group net result increased by 20% to EUR 45 million, with earnings per share rising to EUR 4.62.
Negative Updates
Challenges in Basics & Intermediates Segment
The Basics & Intermediates segment saw an 8% decline in sales compared to the previous year, impacted by the European steel industry's economic difficulties.
Impact of High Electricity Costs
High electricity costs impacted the Basics & Intermediates segment, leading to a decline in EBITDA margin compared to the previous year.
Potential Impact of U.S. Dollar Weakness
The company noted potential negative impacts from the weakening U.S. dollar on sales and costs.
Reduced Sales in Other & Holding Segment
Sales in the Other & Holding segment decreased due to reduced electricity grid fees for chemical park customers.
Company Guidance
In the recent earnings call for AlzChem Group AG, the management provided detailed guidance for the fiscal year 2025, focusing on the third quarter results. The group reported a sales increase of 6% for the third quarter, contributing to a 2% rise over the nine-month period, primarily driven by a 9% growth in their Specialty Chemicals segment. EBITDA rose by 12% to EUR 86 million, with the EBITDA margin improving from 18.5% to 20.3%. The company confirmed their sales outlook, albeit at the lower threshold, but anticipated increased earnings. The ongoing CapEx activities, including the construction of two new plants, are on schedule, while discussions for a U.S. expansion are underway. The demand for creatine products remains robust, reflected in the successful commissioning of incremental capacity. Additionally, a new partnership with Ehrmann to introduce high-protein creatine products could further boost growth. Overall, AlzChem is poised for continued expansion, underlined by strategic investments and a strong market position in specialty chemicals.AlzChem Group AG Financial Statement Overview
Summary
AlzChem Group AG exhibits impressive financial health with strong revenue growth, efficient cost management, and improved profitability. The balance sheet reflects a stable financial position with manageable leverage, and cash flow metrics indicate robust cash generation, supporting sustainable growth.Income Statement
AlzChem Group AG has demonstrated strong revenue growth, with a significant increase from 2023 to 2024. The gross profit margin is healthy, indicating efficient cost management. The net profit margin has improved, showcasing enhanced profitability. Both EBIT and EBITDA margins are strong, reflecting effective operational performance.88
Very Positive
Balance Sheet
The company's balance sheet shows a moderate debt-to-equity ratio, indicating manageable leverage. Return on equity has improved, demonstrating efficient use of equity capital. The equity ratio is stable, supporting asset financing through equity.75
Positive
Cash Flow
AlzChem Group AG has shown robust growth in free cash flow, signifying improved operational efficiency. The operating cash flow to net income ratio is strong, indicating effective cash generation from operations. Free cash flow to net income ratio highlights the company's ability to convert earnings into cash flow.82
Very Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 553.74M | 554.23M | 540.65M | 542.22M | 422.29M | 379.26M |
| Gross Profit | 349.40M | 163.08M | 304.07M | 282.72M | 268.34M | 250.58M |
| EBITDA | 104.75M | 103.96M | 81.75M | 68.06M | 61.89M | 51.39M |
| Net Income | 57.92M | 54.08M | 34.62M | 30.05M | 27.59M | 19.69M |
Balance Sheet | ||||||
| Total Assets | 552.95M | 483.83M | 424.68M | 422.86M | 377.67M | 354.30M |
| Cash, Cash Equivalents and Short-Term Investments | 64.28M | 63.15M | 13.92M | 9.62M | 8.73M | 17.47M |
| Total Debt | 47.72M | 52.82M | 62.49M | 100.23M | 55.64M | 69.06M |
| Total Liabilities | 333.63M | 276.36M | 261.12M | 276.91M | 288.10M | 285.64M |
| Stockholders Equity | 217.30M | 205.54M | 161.63M | 144.01M | 87.63M | 66.89M |
Cash Flow | ||||||
| Free Cash Flow | 42.06M | 62.05M | 52.11M | -33.31M | 14.48M | 19.88M |
| Operating Cash Flow | 112.56M | 105.15M | 72.67M | -4.24M | 43.02M | 48.71M |
| Investing Cash Flow | -59.05M | -30.99M | -20.55M | -28.51M | -28.48M | -28.83M |
| Financing Cash Flow | -34.74M | -24.66M | -49.17M | 33.65M | -23.62M | -11.73M |
AlzChem Group AG Technical Analysis
Negative
140.00
Price Trends
148.20
Negative
147.65
Negative
123.69
Positive
Market Momentum
-0.86
Positive
39.68
Neutral
4.20
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:ACT, the sentiment is Negative. The current price of 140 is below the 20-day moving average (MA) of 154.55, below the 50-day MA of 148.20, and above the 200-day MA of 123.69, indicating a neutral trend. The MACD of -0.86 indicates Positive momentum. The RSI at 39.68 is Neutral, neither overbought nor oversold. The STOCH value of 4.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:ACT.
AlzChem Group AG Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €1.57B | 26.96 | 29.12% | 1.29% | 1.03% | 25.48% | |
70 Neutral | €6.67B | 15.73 | 1.08% | 8.33% | -5.92% | -58.33% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | €6.80B | 16.07 | 9.86% | 4.54% | -1.30% | -28.95% | |
58 Neutral | $3.34B | 13.86 | ― | 3.68% | -10.63% | -23.15% | |
52 Neutral | €10.95B | -29.67 | -5.90% | ― | -1.98% | -16.31% | |
45 Neutral | $1.47B | ― | -3.72% | 0.58% | -2.75% | 83.47% |
* Basic Materials Sector Average
DE:ACT
AlzChem Group AG
140.00
86.95
163.90%
DE:BNR
Brenntag AG
46.26
-13.08
-22.04%
DE:1COV
Covestro
59.26
1.74
3.03%
DE:EVK
Evonik
14.05
-3.27
-18.90%
DE:LXS
LANXESS
17.18
-6.46
-27.32%
DE:WCH
Wacker Chemie AG
67.85
-7.76
-10.27%
AlzChem Group AG Corporate Events
AlzChem Group AG Reports Strong Specialty Chemicals Growth Amid Challenges
Nov 1, 2025
AlzChem Group AG’s recent earnings call painted a picture of robust growth and strategic advancements, particularly in the Specialty Chemicals segment. The company reported a positive financial performance, bolstered by strategic partnerships and significant investments aimed at future expansion. However, challenges persist in the Basics & Intermediates segment, exacerbated by high electricity costs.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.